Akebia Therapeutics, Inc. (AKBA) vs Greenwich LifeSciences, Inc. (GLSI)
A side-by-side comparison of Akebia Therapeutics, Inc. and Greenwich LifeSciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AKBA
Akebia Therapeutics, Inc.
$0.90HealthcareDelayed quote: Oct 6, 2026, 12:00 PM EDT
GLSI
Greenwich LifeSciences, Inc.
$16.60HealthcareDelayed quote: Oct 6, 2026, 11:59 AM EDT
Total return — AKBA vs GLSI
growth of $100 · dividends reinvested · last 6yAKBA -64.2% (-15.7%/yr)GLSI +238.2% (+22.5%/yr)GLSI compounded faster over this window
Log scale — wide-divergence pair
AKBA GLSI
AKBA vs GLSI: by the numbers
- •GLSI is the larger company ($244M vs $241M market cap).
- •Both run net losses; GLSI's is the smaller (0.00% vs -13.54% net margin).
Metrics side by side
Valuation
| Metric | AKBA | GLSI |
|---|---|---|
| P/S ratio | 1.10 | N/A |
| P/B ratio | 9.63 | 78.17 |
| FCF yield | 16.68% | N/A |
Profitability
| Metric | AKBA | GLSI |
|---|---|---|
| Gross margin | 79.48% | 0.00% |
| Operating margin | 9.95% | 0.00% |
| Net margin | -13.54% | 0.00% |
| ROE | -118.58% | -695.56% |
| ROIC | -7.08% | -701.55% |
Growth (annualized)
| Metric | AKBA | GLSI |
|---|---|---|
| Revenue CAGR (5Y) | -0.26% | N/A |
| Total return CAGR (5Y) | -20.07% | -14.84% |
Frequently asked
- How have AKBA and GLSI total returns compared?
- Over the past 5 years, AKBA delivered -20.07% and GLSI delivered -14.84% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Akebia Therapeutics ROEGreenwich LifeSciences ROEAkebia Therapeutics operating marginGreenwich LifeSciences operating marginAkebia Therapeutics revenue growthGreenwich LifeSciences revenue growthAkebia Therapeutics free cash flowGreenwich LifeSciences free cash flow
Akebia Therapeutics & Greenwich LifeSciences appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.